China Drug Approvals

top of page

China NMPA Approves Pfizer’s Matazisimab (You Ruiting) for Routine Prophylaxis in Hemophilia Patients with Inhibitors | iPharmaCenter

Badari Andukuri

4 days ago

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

ipharmaservices

Jan 7

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter

ipharmaservices

Jan 7

HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter

ipharmaservices

Dec 7, 2024

HUTCHMED Announces Continued Inclusion of Savolitinib in China’s National Reimbursement Drug List at Current Terms | China NRDL 2024 | iPharmaCenter

ipharmaservices

Dec 7, 2024

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

China's 2024 National Reimbursement Drug List Expands Access to 91 New Drugs | iPharmaCenter

ipharmaservices

Dec 7, 2024

AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter

ipharmaservices

Oct 14, 2024

China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter

ipharmaservices

Aug 24, 2024

Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter

ipharmaservices

Aug 13, 2024

HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter

ipharmaservices

Jul 8, 2024

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

ipharmaservices

Jul 2, 2024

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

ipharmaservices

Jun 26, 2024

China Drug Approvals | 2024 | iPharmaCenter

China Drug Approvals | 2024 | iPharmaCenter

China Drug Approvals | 2024 | iPharmaCenter

ipharmaservices

May 13, 2024

China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

China Drug Approvals | 2023 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

ipharmaservices

Dec 31, 2023

China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

China Drug Approvals | 2022 | NMPA Drug Approvals | Pharma | Healthcare | China | iPharmaCenter

ipharmaservices

Mar 16, 2023

China Healthcare News | Drug News | iPharmaCenter

China Healthcare News | Drug News | iPharmaCenter

China Healthcare News | Drug News | iPharmaCenter

ipharmaservices

Dec 28, 2022

bottom of page